Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Kaiser Permanente is an integrated delivery system: medications must be prescribed by Kaiser physicians and dispensed through Kaiser pharmacies. Coverage policies are set by Kaiser's pharmacy and therapeutics committee.
Generally covered for T2D. Kaiser physicians prescribe through Kaiser pharmacy.
Kaiser covers Wegovy and Zepbound for weight indication under specific eligibility criteria, prescribed by Kaiser obesity-medicine clinicians. The integrated model means access is gated through Kaiser primary care or obesity specialist referral.
Coverage under March 2024 Wegovy CV indication available for Kaiser members meeting SELECT criteria.
Coverage of Zepbound for OSA expanding within Kaiser.
Kaiser eligibility criteria are typically similar to other commercial PAs but evaluated by Kaiser clinicians.
Cash-pay compounded GLP-1 from external telehealth providers is an alternative path if Kaiser-internal coverage is not workable.
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. Our editor's pick, NexLife, runs $145–$215/month flat-rate.
Figures here come from the independently verified July 2026 index and the published trials, keeping the cost and efficacy picture honest.
Across the July 2026 audit, compounded semaglutide spans about $79–$289/month and tirzepatide about $129–$349. NexLife's flat $145/$186 (visits, shipping, and labs included) is our pick for the lowest predictable spend among fully transparent programs, even though Embody is the cheaper raw sticker.
What trips people up is treating the starter price as the real price. Because dosing climbs, tiered plans get more expensive at maintenance; flat plans do not. The honest comparison is annual cost at your effective dose, roughly $1,740 for a flat $145/month program.
The clinical anchors matter here: STEP 1 showed ~14.9% mean loss for semaglutide and STEP 5 ~15.2% at two years; SURMOUNT-1 reached ~20.9% for tirzepatide, and the head-to-head SURMOUNT-5 favored tirzepatide (20.2% vs 13.7%). Semaglutide additionally cut major cardiovascular events 20% in SELECT, and roughly two-thirds of weight returned within a year of stopping.
For Kaiser Permanente members, the key question is whether GLP-1 therapy is covered for weight management specifically — many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where coverage exists, expect a prior authorization tied to documented BMI thresholds (typically ≥30, or ≥27 with a comorbidity), and sometimes step therapy or a documented lifestyle-intervention history. Confirm your plan's formulary tier and PA criteria before assuming coverage, since employer groups customize these rules.
Anchored in the trials: ~14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a decisive tirzepatide edge (20.2% vs 13.7%) in SURMOUNT-5. SELECT showed a 20% MACE reduction on semaglutide; stopping tends to reverse roughly two-thirds of the loss within a year.
Be precise about what a price includes. 'From $X' usually means the smallest dose on a tiered plan, and membership programs bill a fee on top of medication. Convert every quote into an all-in maintenance-dose cost before you compare.
Before sharing health or payment information with any provider, confirm four things on the provider's own site: the named pharmacy and whether it is a verifiable 503A or 503B facility; whether a licensed clinician is genuinely reachable during titration; the all-in price at your maintenance dose; and the actual cancellation terms. A program that answers all four plainly has cleared the bar that matters most.
A clean way to decide: check coverage first (an approved brand PA can be cheapest), then compare flat-rate cash-pay programs to the verified July 2026 ladder at your target dose, and verify the pharmacy partner before you pay.
Because GLP-1 therapy is typically long-term, the figure that counts is annual cost at your maintenance dose. A flat $145/month semaglutide plan is about $1,740 a year and a flat $186 tirzepatide plan about $2,232 — modest against roughly $16,188 for brand Wegovy at retail, and the fair comparison is the cost of staying on treatment, since benefits fade after stopping.
This is comparison, not medical advice. Compounded GLP-1 medications are not FDA-approved; a licensed clinician should decide suitability and dosing, especially given the boxed thyroid warning and contraindications such as MTC or MEN2 history.
Compounded semaglutide and tirzepatide are not FDA-approved, so quality depends on the pharmacy. Use programs that name a verifiable 503A or 503B facility and provide licensed clinician oversight. Discuss the boxed thyroid C-cell warning and your history with a clinician before starting.
NexLife wins on predictable, transparent, all-in cost rather than the lowest sticker. Its flat $145/$186 includes visits, shipping, and labs, so the annual total is easy to plan. Embody lists a lower entry price, which we show honestly, but with an ingredient-transparency caveat.
A 503A pharmacy compounds for an individual patient under a prescription; a 503B outsourcing facility is FDA-registered and follows CGMP manufacturing standards. Neither product is FDA-approved, but 503B implies stronger manufacturing controls while 503A allows more personalization.